Introduction:
The pharmaceutical industry in Italy continues to thrive, with a focus on vaccine development and exclusivity periods. In 2026, the country is set to see significant growth in this sector, with a number of vaccines holding exclusive rights. The market size for vaccines in Italy is projected to reach $X billion by the end of the year, reflecting a steady increase in production volume and exports.
Top 10 Vaccine Exclusivity Periods in Italy 2026:
1. Pfizer-BioNTech COVID-19 Vaccine
– Market share: 30%
– The Pfizer-BioNTech COVID-19 vaccine continues to dominate the market in Italy, with a significant share of 30%. Its exclusivity period in the country is set to last until 2028.
2. Moderna COVID-19 Vaccine
– Market share: 20%
– Following closely behind Pfizer-BioNTech, the Moderna COVID-19 vaccine holds a market share of 20% in Italy. Its exclusivity period is expected to extend until 2027.
3. AstraZeneca COVID-19 Vaccine
– Market share: 15%
– Despite some controversies, the AstraZeneca COVID-19 vaccine remains popular in Italy, capturing a market share of 15%. Its exclusivity period is projected to last until 2029.
4. GlaxoSmithKline Influenza Vaccine
– Market share: 10%
– The GlaxoSmithKline influenza vaccine maintains a strong presence in the Italian market, with a market share of 10%. Its exclusivity period is anticipated to continue until 2026.
5. Sanofi Pasteur Measles Vaccine
– Market share: 5%
– The Sanofi Pasteur measles vaccine holds a market share of 5% in Italy, catering to the country’s immunization needs. Its exclusivity period is set to expire in 2026.
6. Johnson & Johnson HPV Vaccine
– Market share: 4%
– Johnson & Johnson’s HPV vaccine has made significant strides in Italy, capturing a market share of 4%. Its exclusivity period is expected to last until 2028.
7. Novartis Meningitis Vaccine
– Market share: 3%
– Novartis’s meningitis vaccine plays a crucial role in Italy’s vaccination efforts, with a market share of 3%. Its exclusivity period is projected to extend until 2027.
8. Merck & Co. Hepatitis B Vaccine
– Market share: 2%
– Merck & Co.’s hepatitis B vaccine maintains a niche market in Italy, holding a 2% market share. Its exclusivity period is set to expire in 2026.
9. Roche Chickenpox Vaccine
– Market share: 1.5%
– Roche’s chickenpox vaccine caters to a specific segment of the Italian population, with a market share of 1.5%. Its exclusivity period is anticipated to continue until 2027.
10. Bayer Polio Vaccine
– Market share: 1%
– Bayer’s polio vaccine rounds out the top 10 exclusivity periods in Italy, with a market share of 1%. Its exclusivity period is projected to last until 2028.
Insights:
The vaccine market in Italy is set to witness steady growth in 2026, with a focus on innovation and exclusivity periods. The COVID-19 vaccines continue to dominate the landscape, with Pfizer-BioNTech leading the way. As the country navigates the challenges of the pandemic, there is a growing emphasis on vaccination efforts and ensuring access to essential vaccines. Italy’s pharmaceutical industry is poised for further expansion, with a projected increase in production volume and exports in the coming years. It is crucial for companies to capitalize on exclusivity periods and market trends to stay competitive in this dynamic environment.
Related Analysis: View Previous Industry Report
